Efficacy of sipulin combined with capecitabine or docetaxel chemotherapy in treatment of anthracycline relapsed and metastatic breast cancer / 中国基层医药

ABSTRACT

Objective To evaluate the possible auxiliary effect of sipulin in treatment of anthracycline relapsed and metastatic breast cancer. Methods Sixty-three patients were randomly divided into two groups sipulin groupsipulin plus docetaxel + capecitabine;control grouponly administered with docetaxel + capecitabine. The leukocyte, haemoglobin and platelet,toxicity of digestive tract, body weight, Karnofsky status and efficacy of those patients were evaluated respeoively before and after therapy. Results Overall response rates were 71.9% and 54.8% (P = 0.014)for sipulin group and control group, respectively. The median survival time was 15.9 months versus 11.3 months(P=0. 026)for sipulin group and control group,respectively. The 1-year survival rate for sipulin group and control group was 51.6% versus 38.7% (P = 0.035) ,respectively. The clinical efficacy and reduce of leukocyte were better in sipulin group than in control group, the life quality and clinical symptom of the patients in sipulin group were improved more significantly than those in control group (P ＜ 0. 05, P ＜ 0. 01), the value of CD3, CD4, CD3/CD4 and NK in sipulin group were significantly higher than in control group(P ＜ 0.05). Conclusion Sipulin plus docetaxel/capecitabine regimens could improve the efficacy, reduce the toxicities of digestive tract and blood, enhance the immune function and improve life quality, improve the tolerance of relapsed and metastatic breast cancer patients for chemotherapy and should be recommended.